Establishment and application of drug use evaluation standard of somatostatin for injection

Published on Apr. 29, 2024Total Views: 1484 times Total Downloads: 837 times Download Mobile

Author: ZHANG Jiehong ¹ CAI Huiya ² CAI Liping ¹ HAN Yibo ¹  ZHANG Jinhua ³

Affiliation: 1. Department of Pharmacy, People's Hospital of Beihai, Beihai 536000, Guangxi Zhuang Autonomous Region, China 2. Department of Pharmacy, Second People's Hospital of Zhangzhou, Zhangzhou 363199, Fujian Province, China 3. Department of Pharmacy, Fujian Maternity and Child Health Care Hospital, Fuzhou 350000, China

Keywords: Somatostatin for injection Drug use evaluation standard Rational drug use

DOI: 10.12173/j.issn.1005-0698.202306024

Reference: ZHANG Jiehong, CAI Huiya, CAI Liping, HAN Yibo, ZHANG Jinhua.Establishment and application of drug use evaluation standard of somatostatin for injection[J].Yaowu Liuxingbingxue Zazhi,2024, 33(4):381-387.DOI: 10.12173/j.issn.1005-0698.202306024.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Objective To establish the drug use evaluation(DUE) standard of somatostatin and evaluate the rationality of its clinical use,so as to provide a reference for the rationally clinical application of somatostatin.

Methods Based on the specification of somatostatin for injection, related guidelines and literature, DUE standard was established.Evaluate the rationality and standardization of the use of somatostatin for injection at Beihai People's Hospital from January 2021 to December 2021 based on the established DUE standards.

Results A total of 407 patients were included, with a medication reasonable rate of 94.84%. The irrational use of drug included unreasonable indications (13 cases, 3.19%), unreasonable drug use frequency (7 cases, 1.72%), and unreasonable drug interactions (1 case, 0.25%).

Conclusion The somatostatin for injection DUE standard established is feasible and practical. The clinical application of somatostatin for injection in this hospital is basically reasonable, but there are still some irrational use of somatostatin, which should be strengthened for intervention.

Full-text

Please download the PDF version to read the full text: download

References

1.Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone[J]. Science,1973, 179(4068): 77-79. DOI: 10.1126/ science.179.4068.77.

2.Patel YC. Somatostatin and its receptor family[J]. Front Neuroendocrinol, 1999, 20(3): 157-198. DOI: 10.1006/frne.1999.0183.

3.Colao A, Faggiano A, Pivonello R. Somatostatin analogues: treatment of pituitary and neuroendocrine tumors[J]. Prog Brain Res, 2010, 182: 281-294. DOI: 10.1016/S0079-6123(10)82012-6.

4.Bhasin DK, Siyad I. Variceal bleeding and portal hypertension: new lights on old horizon[J]. Endoscopy, 2004, 36(2): 120-129. DOI: 10.1055/s-2004-814179.

5.Liguz-Lecznar M, Dobrzanski G, Kossut M. Somatostatin and somatostatin-containing interneurons-from plasticity to pathology[J]. Biomolecules, 2022, 12(2): 312. DOI: 10.3390/ biom12020312.

6.吴美强. 生长抑素及类似物的临床应用进展[J].中国现代药物应用, 2010, 4(23): 235-237. [Wu MQ. Progress in clinical application of somatostatin and its analogues[J]. Chinese Journal of Modern Drug Application, 2010, 4(23):235-237.] DOI: 10.3969/j.issn.1673-9523.2010. 23.223.

7.赵洪礼, 吴战军, 谢艳娜. 生长抑素临床应用研究进展[J]. 齐鲁药事, 2009, 28(7): 416-419. [Zhao HL, Wu ZJ, Xie YN. Progress in the clinical research of somatostatin[J]. Qilu Pharmaceutical Affairs, 2009, 28(7): 416-419.] DOI: 10.3969/j.issn. 1672-7738.2009.07.016.

8.李素琼, 班立丽. 国内外药物利用评价研究综述[J]. 中国医院用药评价与分析, 2021, 21(7): 893-896.[Li SQ, Ban LL. Review on drug use evaluation at home and abroad[J]. Evaluation and Analysis of Drug-use in Hospitals of China, 2021, 21(7): 893-896.] DOI: 10.14009/ j.issn.1672-2124.2021.07.028.

9.中华医学会消化病学分会胰腺疾病学组, 中华胰腺病杂志编辑委员会, 中华消化杂志编辑委员会. 中国急性胰腺炎诊治指南(2019年, 沈阳)[J]. 中华消化杂志, 2019, 39(11): 721-730. DOI: 10.3760/cma.j.issn. 0254-1432.2019.11.001.

10.中华医学会急诊分会, 京津冀急诊急救联盟, 北京医学会急诊分会, 等. 急性胰腺炎急诊诊断及治疗专家共识[J]. 中华急诊医学杂志, 2021, 30(2): 161-172. DOI: 10.3760/cma.j.issn.1671-0282.2021.02.005.

11.广东省药学会. 超药品说明书用药目录(2022年版新增用法)[J]. 今日药学, 2022, 32(6): 401-408. DOI: 10.12048/j.issn.1674-229X.2022.06.001.

12.中华医学会消化内镜学分会结直肠学组, 中国医师协会消化医师分会结直肠学组, 国家消化系统疾病临床医学研究中心. 下消化道出血诊治指南(2020) [J]. 中国医刊, 2020, 55(10): 1068-1076. DOI: 10.3969/j.issn. 1008-1070.2020.10.007.

13.刘冠云, 谢爱玲. 生长抑素治疗粘连性肠梗阻效果的meta分析[J]. 中国生化药物杂志, 2016, 36(8): 160-164. [Liu GY, Xie AL. Effects of somatostatin in adhesive intestinal obstruction-a meta analysis[J]. Chinese Journal of Biochemical and Pharmaceutics, 2016, 36(8): 160-164.] DOI: 10.3969/j.issn.1005-1678.2016.08.045.

14.张翔, 白錬, 简斌, 等. 生长抑素治疗恶性肠梗阻患者疗效的Meta分析[J]. 西部医学, 2018, 30(12): 1810-1816. [Zhang X, Bai X, Jian B, et al. Somatostatin for magligant bowel obstruction: a systematic review[J]. Medical Journal of West China, 2018, 30(12): 1810-1816.] DOI: 10.3969/j.issn.1672-3511.2018.12.021.

15.Li Z, Liu Z, Yu Z. Application effect of somatostatin combined with transnasal ileus catheterization in patients with acute intestinal obstruction and advanced gastric cancer[J]. Comput Intell Neurosci, 2022, 2022: 9747880. DOI: 10.1155/2022/9747880.

16.Dou C, Li K, Wang L. Computed tomography image segmentation of the proximal colon by U-net for the clinical study of somatostatin combined with intestinal obstruction catheter[J]. Comput Math Methods Med, 2022, 2022: 6868483. DOI: 10.1155/2022/6868483.

17.Jackson CS, Gerson LB. Management of gastrointestinal angiodysplastic lesions (GIADs): a systematic review and meta-analysis[J]. Am J Gastroenterol, 2014, 109(4): 474-484. DOI: 10.1038/ajg.2014.19.

18.Grooteman KV, van Geenen EJ, Drenth JP. Multicentre, open-label, randomised, parallel-group, superiority study to compare the efficacy of octreotide therapy 40 mg monthly versus standard of care in patients with refractory anaemia due to gastrointestinal bleeding from small bowel angiodysplasias: a protocol of the OCEAN trial[J]. BMJ Open, 2016, 6(9): e011442. DOI: 10.1136/bmjopen- 2016-011442.

19.Kumar A, Artifon E, Chu A, et al. Effectiveness of endoclips for the treatment of stigmata of recent hemorrhage in the colon of patients with acute lower gastrointestinal tract bleeding[J]. Dig Dis Sci, 2011, 56(10): 2978-2986. DOI: 10.1007/s10620-011-1683-1.

20.Chetcuti Zammit S, Sanders DS, Sidhu R. Lanreotide in the management of small bowel angioectasias: seven-year data from a tertiary centre[J]. Scand J Gastroenterol, 2017, 52(9): 962-968. DOI: 10.1080/00365521.2017.1325929.

21.Tarasconi A, Coccolini F, Biffl WL, et al. Perforated and bleeding peptic ulcer: WSES guidelines[J]. World J Emerg Surg, 2020, 15: 3. DOI: 10.1186/s13017-019-0283-9.

22.赵序云. 生长抑素在保守治疗消化性溃疡穿孔的研究[J]. 中外医疗, 2013, 32(16): 103-104. [Zhao XY. Study on somatostatin's action in conservative treatment of peptic ulcer perforation[J]. China & Foreign Medical Treatment, 2013, 32(16): 103-104.] DOI: 10.3969/j.issn.1674-0742.2013.16.064.

23.Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects[J]. Gut, 1994, 35(3 Suppl): S1-4. DOI: 10.1136/gut.35.3_suppl.s1.

24.Ripamonti C, De Conno F, Boffi R, et al. Can somatostatin be administered in association with morphine in advanced cancer patients with pain?[J]. Ann Oncol, 1998 ,9(8): 921-923. DOI: 10.1023/a:1008416621421.

25.怀一胜, 温红珠, 曲环汝. 生长抑素引起的血压升高、心动过缓并发低血糖1例[J]. 中国药师, 2022, 25(5): 854-855. [Huai YS, Wen HZ, Qu HR. One case of elevated blood pressure, bradycardia, and hypoglycemia caused by somatostatin[J]. China Pharmacist, 2022, 25(5): 854-855.] DOI: 10.19962/j.cnki.issn1008-049X.2022.05.019.

26.徐华, 陈易, 金颖, 等. 生长抑素及其类似物奥曲肽治疗急性胰腺炎时诱发的低血糖[J]. 中华胰腺病杂志, 2014, 14(2): 117-119. [Xu H, Chen Y, Jin Y, et al. Hypoglycemia induced by somatostatin and its analogue octreotide in the treatment of acute pancreatitis[J]. Chinese Journal of Pancreatology, 2014, 14(2): 117-119.] DOI: 10.3760/cma.j.issn.1674-1935.2014. 02.014.

27.赵西峰, 毛淑敏. 34例注射用生长抑素致低血糖不良反应分析[J]. 中国处方药, 2021, 19(3): 64-66. [Zhao XF, Mao SM. Analysis of 34 cases of hypoglycemic adverse reactions caused by injection of somatostatin[J]. Journal of China Prescription Drug, 2021, 19(3): 64-66.] DOI: 10.3969/j.issn.1671-945X.2021.03.032.

28.肖招英. 微量泵持续静脉注射生长抑素治疗消化道出血致低血糖24例分析[J]. 中国基层医药, 2013, 20(12): 1897-1898. [Xiao ZY. Analysis of 24 cases of hypoglycemia caused by gastrointestinal bleeding treated by continuous intravenous injection of somatostatin with micropump[J]. Chinese Journal of Primary Medicine and Pharmacy, 2013, 20(12): 1897-1898.] DOI: 10.3760/cma.j.issn.1008-6706.2013.12.073.

29.王春婷, 马敏康, 郑明节. 注射用生长抑素安全性风险分析[J]. 中国药物警戒, 2021, 18(11): 1080-1082, 1086. [Wang CT, Ma MK, Zheng MJ. Safety risks of somatostatin for injection[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1080-1082.] DOI: 10.19803/j.1672-8629.2021.11.18.

30.李红梅, 张亚波. 持续泵入生长抑素时防止发生低血糖的方法[J]. 实用临床医药杂志, 2012, 16(16): 122-123. [Li HM, Zhang YB. Preventing hypoglycemia reactions with continuous pumping of somatostatin[J]. Journal of Clinical Medicine in Practice, 2012, 16(16): 122-123.] DOI: 10.3969/j.issn.1672-2353.2012.16.051.

31.夏世萍, 赵柱莲. 生长抑素静滴的滴速与不良反应[J]. 医学理论与实践, 2010, 23(5): 595-596. [Xia SP, Zhao ZL. Dropping rate and adverse reactions of somatostatin intravenous drip[J]. Journal of Medical Theory and Practice, 2010, 23(5): 595-596.] DOI: 10.3969/j.issn.1001-7585.2010.05.079.